Description

Incyte’s Opzelura Opportunity Is Getting Bigger—How Much Upside Does Moderate AD Unlock Internationally?

Incyte Corporation reported robust financial performance and strategic advancements in their fourth quarter and full-year 2025 results, illustrating both progress and challenges. The company achieved significant sales growth, driven primarily by the strong performance of its flagship product, Jakafi, and substantial contributions from its core business excluding Jakafi. Total revenues for the fourth quarter reached $1.51 billion, marking a 28% increase year-over-year, while full-year revenues grew by 21% to $5.14 billion. Net sales for the year were $4.35 billion, representing a 20% year-over-year growth, propelled by successful product launches and the expansion of its product pipeline. Jakafi, Incyte’s leading product, recorded a 11% growth in annual sales, totaling $3.093 billion. The company anticipates Jakafi’s net sales to be within $3.22 billion to $3.27 billion for 2026, expecting high single-digit prescription growth.